## Nixon & Vanderhye Ec.

ATTORNEY AT LAW

8TH FLOOR 1100 NORTH GLEBE ROAD ARLINGTON, VIRGINIA 22201-4714 TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100 WRITER'S DIRECT DIAL NUMBER: (703) 816-4011

# FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

Atty Dkt.:	1579-548					
,,		Date:	July 28, 2003			
To:	Examiner Stucker - Group: 1648					
Firm:	USPTO					
Facsimile No.:	(703) 746-5182					
From:	Mary J. Wilson					
Number of Pa (IF YOU DO NOT RECEIV PLEASE CONTACT US IM	ges (including E ALL OF THE PA IMEDIATELY AT (1	GES OR ENCOUNTER	23 DIFFICULTIES IN TRANSMISSION,			
		•	Tabitha A. Trice			
		F	ACSIMILE OPERATOR			
ATTACHMENT/S: OFFICIAL SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT W/PTO-1449 FORM (IN DUPLICATE) AND REFERENCE						
MESSAGE:						
In re PATENT APPL	ICATION OF:		·			
HAYNES et al	05					

#### CONFIDENTIALITY NOTE

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. If YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for return of the original documents to us.

Filed: February 5, 2001

Jul 28 200

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-548

C# M#

HAYNES et al

Group Art Unit: 1648

Serial No. 09/775,805

Examiner: Stucker, J.

Filed: February 5, 2001

Date: July 28, 2003

Title:

HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

algrature arouse			
☐ Correspondence Address Indication Form Attached.			
Fees are attached as calculated below:  Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00	
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	<b>\$</b> .	0.00	
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00	
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)			
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00	
First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00)  Please enter the previously unentered , filed	\$	0.00	
Submission attached Subtotal			
If "small entity," then enter half (1/2) of subtotal and subtract  Applicant claims "small entity" status.  Statement filed herewith	-\$	0.00	
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00	
Assignment Recording Fee (\$40.00)	\$	0.00	
Other:		0.00	
TOTAL FEE ENCLOSED	\$	0.00	

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

758415

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re F	Patent Ap	oplication of					
HAYN	IES et al		Atty. Ref.:	1579-548			
Serial	No.	09/775,805	Group:	1648			
Filed:	Fel	bruary 5, 2001	Examiner:	Stucker, J.			
For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE							
		* * * * * * * *	. * * *				
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  July 28, 2003							
			<b>34.7 23,</b> 23,				
Sir: <u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>							
	1.	PTO-1449 Pursuant to 37 CFR 1.97(I within 3 months of filing or prior to 1st	b) Office Action	on the merits			
	2.(a)	Statement Pursuant to 37 CFR 1.97 [before Final Office Action or Allowand Statement or Rule 17(p) fee)]	c) e (requires R	ule 97(e) N/C			
$\boxtimes$	2 .(b)	Fee Payment Pursuant to 37 CFR 1. [before Final Office Action or Allowand Statement or Rule 17(p) fee)]	<b>97(c)</b> ce (requires R	ule 97(e) \$180.00			
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance Statement and Rule 17(p) fee), but be	(requires Rul fore final fee	e 97(e) payment] \$180.00			

08/06/2003 NVILLARI 00000002 141140 09775805

01 FC:1806

180.00 DA

The following are submitted in the above-identified application in compliance with

37 C.F.R. §§ 1.97 and 1.98: A list of documents on Form PTO-1449 together with copies of each M identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with: 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] 5. П 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; X 6. and The regulred Statement made in item 8 below; or a) The \$180,00 fee specified in 37 CFR §1.17(p) for submission of this 冈 b) Information Disclosure Statement is authorized in item 9 below. 7. 37 CFR §1,97(d): [after Final Office Action or Allowance (requires Rule 97(e) П Statement and Rule 17(p) fee), but before final fee payment]; and The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; a) and П b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or П No item of information contained in this Information Disclosure Statement

Disclosure Statement.

was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information

contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information



While no further fee is believed to be required, if the Office takes a different  $\boxtimes$ 9. view, authorization is hereby given to charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

The Examiner's attention is directed to the following co-pending cases:

Respectfully submitted, **NIXON & VANDERHYE P.C.** 

Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100